What was the impact of the Wainua trial failure on AstraZeneca's stock and market value?

The unexpected failure of the nerve drug Wainua in a late-stage heart disease trial hammered AstraZeneca's shares, contributing to a 10% year-to-date decline and causing the stock to trail both GSK and the wider London stock index over two years; the setback erased approximately $20 billion of the firm's market value.

Why are the upcoming SERENA-4 and AVANZAR trial results considered critical for investor confidence in AstraZeneca?

SERENA-4 (a breast cancer study) and AVANZAR (a lung cancer trial) are among AstraZeneca's most closely watched late-stage oncology trials due to report this year; successful results would bolster confidence in the company's ability to replace blockbuster medicines losing patent protection in the next decade, while failures — especially following the Wainua setback — could raise questions about clinical trial design, pipeline selection, and long-term sales ambitions, with AVANZAR’s outcome particularly important for validating the firm’s proprietary biomarker used across future oncology trials.

AstraZeneca 'Magic' Faces Rare Test After Trial Failure, Shares Slide

Jul 23, 2026

AstraZeneca shares fell 10% after its nerve drug Wainua failed a Phase III heart disease trial, erasing $20 billion in market value. Investors now await results from key oncology trials SERENA-4 and AVANZAR to gauge the firm's R&D pipeline health.

reuters

2026-07-09

European Shares Gain as Tech Stocks Rebound; Middle East in Focus

2026-07-09

London's FTSE 100 Slips as Middle East Tensions Persist, AstraZeneca Drags

2026-07-23

AstraZeneca 'Magic' Faces Rare Test After Trial Failure, Shares Slide

2026-09-17

AstraZeneca-Daiichi breast cancer drug cleared for NHS use in England

AstraZeneca 'Magic' Faces Rare Test After Trial Failure, Shares Slide

FAQ